Core Insights - The stock of Qiming Medical-B (02500) rose over 7%, reaching HKD 2.44 with a trading volume of HKD 4.5441 million, following the announcement of positive mid-term clinical results for the Cardiovalve transcatheter tricuspid valve replacement system [1] Group 1: Clinical Trial Results - The TARGET study is a prospective, multi-center, single-arm clinical trial conducted across 25 centers in Germany, Spain, Italy, Canada, and the UK, involving 125 patients with an average age of 77 [1] - The average procedure time was reported at 58±29 minutes, with an intraoperative success rate of 88% and an implantation success rate of 95% [1] - At the 6-month follow-up, 100% of patients showed no moderate or severe regurgitation, with 88% improving to New York Heart Association (NYHA) functional class I/II, increasing to 90% at 12 months, and an average quality of life score improvement of 20 points [1] Group 2: Safety and Efficacy - The overall mortality rate was 6.4% (8 out of 125), with a heart failure readmission rate of 1.6%, and low incidence rates for pericardial effusion, disabling stroke, and acute kidney injury requiring renal replacement therapy [2] - The mid-term clinical data for the Cardiovalve system received high recognition from international clinical experts at the PCR London Valves 2025 conference, showcasing its excellent clinical efficacy in treating severe tricuspid regurgitation [2] - The company plans to continue advancing the global clinical registration and development process for innovative products, including the Cardiovalve system [2]
港股异动 | 启明医疗-B(02500)涨超7% Cardiovalve三尖瓣置换系统中期临床显示安全及疗效良好